The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Paresh Vyas, University of Oxford, Oxford, UK. We asked: What mechanisms lead to AML transformation in Down's syndrome AML?
Up to 30% of newborn babies with Down's syndrome exhibit genetic aberrations in the Gas1 gene. However, at 3 months, most children test negative for these mutations, and only a small proportion persist. This population of children will likely acquire further mutational changes, the range of which have now been identified. The identification of mutational patterns in children with Down's syndrome that progress to AML has allowed for directed, personalized treatment and, therefore, fewer toxicities and favorable survival outcomes.
What mechanisms lead to AML transformation in Down's syndrome AML?